Charles Mills

Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.

Regeneration Technologies, Inc. (RTI) is engaged in tissue-based innovations that are used to repair and promote the natural healing of human bone and other human tissues. RTI processes human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, pericardial and cardiovascular tissue in producing allograft implants. RTI's patented BioCleanse® tissue sterilization process is validated to eliminate bacteria, fungi, spores and viruses from the tissue. The company is located in Alachua, FL.

KeraLink International, Inc. operates as a non-governmental network of eye and tissue banks. It also provides ocular tissues used in transplant surgeries. The company was founded in 1962 and is headquartered in Baltimore, MD.

Be The Match Foundation provides bone marrow and cord blood transplant services. The non-profit company is based in Minneapolis, MN.

Be The Match is a non-profit organization that connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. The private company is based in Minneapolis. The American company operates the most diverse registry in the world, which includes both adult donors willing to donate to a stranger in need and stored cord blood units. Be The Match provides patients and their families one-on-one support, education, and guidance before, during, and after transplant. Amy L. Ronneberg has been the CEO of the company since 2013.

Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA.